What is the long-term trend for Ocular Therapeutix's deferred revenue, net of current portion?

Over 5 years (2020 to 2025), Ocular Therapeutix's deferred revenue, net of current portion has grown at a 3.1% compound annual growth rate (CAGR), from $12M to $14M.

Ocular Therapeutix OCUL Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron PharmaceuticalsREGN

$225.1M+6.3%

Envista Holdings CorporationNVST

——

Henry ScheinHSIC

——

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's deferred revenue, net of current portion?: Ocular Therapeutix (OCUL) reported deferred revenue, net of current portion of $14M in Q1 2026.
How has Ocular Therapeutix's deferred revenue, net of current portion changed year-over-year?: Ocular Therapeutix's deferred revenue, net of current portion decreased by 0.0% year-over-year, from $14M to $14M.
What is the long-term trend for Ocular Therapeutix's deferred revenue, net of current portion?: Over 5 years (2020 to 2025), Ocular Therapeutix's deferred revenue, net of current portion has grown at a 3.1% compound annual growth rate (CAGR), from $12M to $14M.